State Street’s AbCellera Biologics ABCL Stock Holding History

State Street’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.74M	Buy	731,362 +1,149	+0.2%	+$5.62K	﹤0.01%	2942
2026 Q1	$2.55M	Buy	730,213 +36,099	+5%	+$130K	﹤0.01%	3220
2025 Q4	$2.37M	Buy	694,114 +23,097	+3%	+$103K	﹤0.01%	3288
2025 Q3	$3.38M	Buy	671,017 +56,724	+9%	+$250K	﹤0.01%	3147
2025 Q2	$2.11M	Sell	614,293 -12,848	-2%	-$32K	﹤0.01%	3299
2025 Q1	$1.4M	Buy	627,141 +302,339	+93%	+$867K	﹤0.01%	3358
2024 Q4	$952K	Buy	324,802 +1,573	+0.5%	+$4.38K	﹤0.01%	3497
2024 Q3	$840K	Buy	323,229 +4,679	+1%	+$13K	﹤0.01%	3515
2024 Q2	$943K	Sell	318,550 -131,705	-29%	-$498K	﹤0.01%	3481
2024 Q1	$2.04M	Sell	450,255 -10,645	-2%	-$54.3K	﹤0.01%	3273
2023 Q4	$2.63M	Buy	460,900 +44,722	+11%	+$207K	﹤0.01%	3224
2023 Q3	$1.91M	Buy	416,178 +163,738	+65%	+$996K	﹤0.01%	3355
2023 Q2	$1.63M	Sell	252,440 -3,137,365	-93%	-$21.4M	﹤0.01%	3473
2023 Q1	$25.6M	Buy	3,389,805 +120,418	+4%	+$1.09M	﹤0.01%	2057
2022 Q4	$33.1M	Buy	3,269,387 +58,568	+2%	+$677K	﹤0.01%	1910
2022 Q3	$31.8M	Buy	3,210,819 +16,510	+0.5%	+$181K	﹤0.01%	1906
2022 Q2	$34M	Buy	3,194,309 +2,925,279	+1,087%	+$24.8M	﹤0.01%	1882
2022 Q1	$2.62M	Buy	269,030 +89,823	+50%	+$850K	﹤0.01%	3468
2021 Q4	$2.56M	Buy	179,207 +52,739	+42%	+$800K	﹤0.01%	3565
2021 Q3	$2.53M	Buy	+126,468	New	+$2.24M	﹤0.01%	3548

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

State Street's ABCL Position: Q2 2026 in Review

State Street increased its AbCellera Biologics (ABCL) stake by 0.16% in Q2 2026, buying an estimated $5.62K and bringing the position to 731,362 shares worth $5.74M. The position accounts for ﹤0.01% of the portfolio, ranked #2942.

State Street first reported a position in ABCL in Q3 2021 and has held it in 20 quarters since. The position peaked at $34M in Q2 2022. 151 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

State Street held 731,362 shares of AbCellera Biologics worth $5.74M as of Q2 2026.
State Street bought 1,149 AbCellera Biologics shares in Q2 2026, an estimated $5.62K.
AbCellera Biologics made up ﹤0.01% of State Street's portfolio in Q2 2026, its #2942 holding.
State Street first reported a position in AbCellera Biologics in Q3 2021 and has held it in 20 quarters since.
State Street's AbCellera Biologics position peaked at $34M in Q2 2022.
151 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.